skip to main content

Publications

Crediting Preemption: Credit Suisse IPO case strengthens the FDA's argument for the preemption of state law failure-to-warn claims

Drug and Device Law

July 30, 2007

Authors: Adam M. Masin

Suggesting that the Supreme Court should view federal preemption issues in the pharmaceutical context based on analogous rationale outside that context.  

Click here for the full article.

Attorneys

© Shipman & Goodwin LLP, 2017. All Rights Reserved.